You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Artificial Salivary Gland Dental Implant
SBC: ORAL FLUID DYNAMICS LLC Topic: NIDCRXerostomiaor dry mouthaffects approximatelyof the U Spopulationsomemillion people by causing oral discomfort and pain due to chronically dry mucosaThis condition leads to oral disease such as caries and candidiasisand has no cure or adequate treatmentMany remedial approaches have been tried with only limited successincluding the provision of fluid to the mouth via frequent sippingvarious mouthwash ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery
SBC: Cavatar LLC Topic: NCIPROJECT SUMMARY This proposal aims to develop a novel caveolae targeting antibody for rapid clinical translationIts long term objective is to develop the caveolae pumping systeman active transendothelial transport pathwayto provide an effective solution to the delivery and toxicity problem of systemically administered chemotoxinsWork will be based on the current proprietary mouse monoclonal antibo ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A user-friendly microfluidic chip for anti-epileptogenic drug screening
SBC: Xona Microfluidics, Inc. Topic: 101New pharmacological treatments for epilepsy will be discovered through the development of new screening platforms that are rapidreliableand can identify novel disease modifying therapiesor anti epileptogenic treatmentsXona MicrofluidicLLCXonais in a unique position to provide such screening tools and services for epilepsy researchXona focuses on the development of microfluidic platforms for neuron ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Direct Delivery of Nucleic Acid Therapeutics
SBC: FHC, INC. Topic: NIMHProject Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic diamond NMR sensor
SBC: ODMR Technologies, Inc Topic: 400Project SummaryNuclear magnetic resonanceNMRis amongst the most powerful analytical techniques ever inventedas recognized byNobel Prizes for methods development aloneNonethelessNMR is notoriously plagued by poor sensitivity and spatial resolutionState of the art NMR spectrometers typically feature detection thresholds ofnanograms forL sample volumesThis places NMR sensitivity many orders of magnit ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Sonomyographic Control of Fiber-Optically Sensorized Prosthetic Fingers for Graded Force Actuation
SBC: INTELLIGENT FIBER OPTIC SYSTEMS CORP Topic: NINDSSonomyographic Control of Fiber Optically Sensorized Prosthetic Fingers for Graded Force Actuation Intelligent Fiber Optic Systems CorporationIFOSCalle del MundoSanta ClaraCAwww ifos com PROJECT SUMMARY ABSTRACTMAXIMUMLINESIn this Phase I SBIR applicationIFOS and George Mason UniversityGMUpropose an innovative control system leveraging on two emerging technologiesultrasonic imaging based readout o ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effects
SBC: VALA SCIENCES, INC. Topic: 101Neurodevelopmental diseasesNDDsAutism Spectrum DisorderASDIntellectual DisabilitiesBipolar disordersand Schizophreniaetcare prevalent and due to errors in neurodifferentiation and neurocircuitryWhile NDDsin many casesare due to inherited mutationsevidence is mounting that prenatal exposure to environmental toxicants also cause NDDs via disruption of epigeneticse gmodifications of histoneshistone t ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a low cost point-of-care device for rapid pathogen detection
SBC: ELECTRONUCLEICS INC Topic: NIAIDProject Summary This project is focused on feasibility testing of a new device based on electromechanical signal transduction for the low cost$in electronicsoptics free and amplification freee gno PCRdetection of DNA RNA at ultralow concentrationThe device addresses the projected $B disease diagnostics market and is well suited for the detection of bacterial pathogens in body fluidsfood and water ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Administrative Supplement to restore fee funds
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDSProject Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
O-Glycan-dependent Immunotherapy for Cancer
SBC: GLYTR THERAPEUTICS, INC. Topic: 102Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health